A 12 week, single centre, open label study to evaluate the effect of fesoterodine flexible dosing regimen on the sexual function of women with overactive bladder.

Trial Profile

A 12 week, single centre, open label study to evaluate the effect of fesoterodine flexible dosing regimen on the sexual function of women with overactive bladder.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Feb 2016 Planned End Date changed from 31 Dec 2015 to 31 Dec 2016, according to United Kingdom Clinical Research Network.
    • 28 Apr 2015 Planned End Date changed from 1 Jun 2015 to 31 Dec 2015 as reported by United Kingdom Clinical Research Network.
    • 05 Mar 2015 Accrual to date is 20% according to United Kingdom Clinical Research Network
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top